A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma

• Todd A. Fehniger,
• Marcus P. Watkins,
• Nkiruka Ezenwajiaku,
• Fei Wan,
• David D. Hurd,
• Amanda F. Cashen,
• Kristie A. Blum,
• Andre Goy,
• Timothy S. Fenske,
• Nina D. Wagner-Johnston,
• Kenneth Carson,
• Marilyn J. Siegel,
• David Russler-Germain,
• Stephanie E. Schneider,
• Neha Mehta-Shah,
• Brad Kahl,
• Nancy L. Bartlett

Affiliations

Todd A. Fehniger

Washington University School of Medicine, Division of Oncology, St. Louis, MO

Marcus P. Watkins

Washington University School of Medicine, Division of Oncology, St. Louis, MO

Nkiruka Ezenwajiaku

Washington University School of Medicine, Division of Oncology, St. Louis, MO

Fei Wan

Washington University School of Medicine, Division of Biostatistics, St. Louis, MO

David D. Hurd

Wake Forest University School of Medicine, Section of Hematology and Oncology, Winston-Salem, NC

Amanda F. Cashen

Washington University School of Medicine, Division of Oncology, St. Louis, MO

Kristie A. Blum

Emory University School of Medicine, Atlanta, GA

Andre Goy

Hackensack University Medical Center, Division of Lymphoma, Hackensack, NJ

Timothy S. Fenske

Medical College of Wisconsin, Hematology and Oncology, Milwaukee, WI

Nina D. Wagner-Johnston

Washington University School of Medicine, Division of Oncology, St. Louis, MO

Kenneth Carson

Washington University School of Medicine, Division of Oncology, St. Louis, MO

Marilyn J. Siegel

Washington University, Mallinckrodt Institute of Radiology, Alvin J. Siteman Cancer Center, St. Louis, MO

David Russler-Germain

Washington University School of Medicine, Division of Oncology, St. Louis, MO

Stephanie E. Schneider

Washington University School of Medicine, Division of Oncology, St. Louis, MO

Neha Mehta-Shah

Washington University School of Medicine, Division of Oncology, St. Louis, MO

Brad Kahl

Washington University School of Medicine, Division of Oncology, St. Louis, MO

Nancy L. Bartlett

Washington University School of Medicine, Division of Oncology, St. Louis, MO